Skip to main content

Table 10 Test 3: Sensitivity Analysis – Changing CATIE Relapse Risk Ratios

From: Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

 

Olanzapine/CATIE Ratio

Cost-Neutral Ratio

Cost-Effective Ratio (ICER @ $50000)

RIS

0.64*

0.65

0.73 ($45,385)

QUE

0.44

0.88

0.89 ($60,767)

ZIP

0.57

0.75

0.80 ($43,236)

ARIP

0.57

0.77

0.80 ($44,187)

  1. *Base case ratio from CATIE Phase 1 [23] which reported hospitalization risk ratios normalized to 1 person year of exposure: RIS = 0.45, OLZ = 0.29 thus olanzapine/risperidone = 0.64.
  2. CATIE = Clinical Antipsychotic Trials of Intervention Effectiveness; ICER = incremental cost-effectiveness ratio; RIS = risperidone; QUE = quetiapine; ZIP = ziprasidone; ARIP = aripiprazole
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us